Stefan Oelrich - Bayer AG Executive

BAYZF Stock  USD 23.55  0.11  0.46%   

Executive

Mr. Stefan Oelrich was Member of the Management Board, Head of the Pharmaceuticals Division of Bayer Aktiengesellschaft since November 1, 2018. After graduating from high school in Paris, France, he joined Bayer AG as a commercial trainee in 1989 and qualified as a commercial assistant in 1991. Over the next 20 years, he held a number of positions of increasing responsibility in the health care business in Latin America, Europe and the United States. In 1998, after working in Argentina and Uruguay, Mr. Oelrich transferred to headquarters in Leverkusen for two years before assuming responsibility for Pharmaceuticals in Belgium. Between 2003 and 2005, he was Vice President of Marketing at Pharmaceuticals in the United States. He was subsequently appointed President of Healthcare and Diagnostics in France. In 2006, Mr. Oelrich returned to the United States as Senior Vice President and General Manager of Womens Healthcare. In 2011, he joined Sanofi as General Manager in Germany, Switzerland and Austria. In 2015, Mr. Oelrich became head of Sanofis Diabetes and Cardiovascular business unit in Europe. At the same time, he served as Sanofi Europe Coordinator. In 2016, Mr. Oelrich became head of Sanofis global diabetes franchise. A year later, he was appointed Executive Vice President Diabetes Cardiovascular on the Executive Committee of Sanofi. Since 2016, Mr. Oelrich was Member of the Supervisory Board of the Berlin Institute of Health. since 2018.
Age 55
Tenure 7 years
Phone49 214 30 1
Webhttps://www.bayer.com

Bayer AG Management Efficiency

The company has return on total asset (ROA) of 0.0576 % which means that it generated a profit of $0.0576 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.13 %, meaning that it generated $0.13 on every $100 dollars invested by stockholders. Bayer AG's management efficiency ratios could be used to measure how well Bayer AG manages its routine affairs as well as how well it operates its assets and liabilities.
Bayer AG has accumulated 35.55 B in total debt with debt to equity ratio (D/E) of 1.17, which is about average as compared to similar companies. Bayer AG has a current ratio of 1.16, suggesting that it is in a questionable position to pay out its financial obligations in time and when they become due. Debt can assist Bayer AG until it has trouble settling it off, either with new capital or with free cash flow. So, Bayer AG's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Bayer AG sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Bayer to invest in growth at high rates of return. When we think about Bayer AG's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Robert CecuttiMagna International
N/A
Neha CPABrunswick
49
John BuelowBrunswick
53
Sarah ArchibongCars Inc
N/A
Tom RuckerMagna International
N/A
Ulrich KammholzPACCAR Inc
N/A
Brent DahlBrunswick
N/A
Rousseau JoosteBarrick Gold Corp
N/A
Samir ShahBrunswick
N/A
Rodney QuickBarrick Gold Corp
48
Sebastiaan BockBarrick Gold Corp
46
Michael BeersPACCAR Inc
N/A
Poupak BahaminBarrick Gold Corp
54
Louis TonelliMagna International
N/A
John SteeleBarrick Gold Corp
59
Grant BeringerBarrick Gold Corp
43
Angelique MarksCars Inc
56
James RogersCars Inc
67
Lois WarkBarrick Gold Corp
69
Sherry SiuEast Africa Metals
55
Tracy FuerstMagna International
N/A
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany. Bayer Ag is traded on OTC Exchange in the United States. Bayer AG [BAYZF] is a Pink Sheet which is traded between brokers over the counter.

Management Performance

Bayer AG Leadership Team

Elected by the shareholders, the Bayer AG's board of directors comprises two types of representatives: Bayer AG inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bayer. The board's role is to monitor Bayer AG's management team and ensure that shareholders' interests are well served. Bayer AG's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bayer AG's outside directors are responsible for providing unbiased perspectives on the board's policies.
Sarena Lin, Labor Officer
Oliver Maier, Head Relations
Gabriel Harnier, Patents Law
Heiko Schipper, Member of the Management Board, Head of the Consumer Health Division
Rodrigo Santos, Member Division
Michael Preuss, Gov Communications
Stefan Oelrich, Member of the Management Board, Head of the Pharmaceuticals Division
Wolfgang Nickl, CFO, Member of the Management Board
BerndPeter Bier, Head Taxes
Werner Baumann, Chief Strategy and Portfolio Officer and Member of Management Board

Bayer Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Bayer AG a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Other Information on Investing in Bayer Pink Sheet

Bayer AG financial ratios help investors to determine whether Bayer Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bayer with respect to the benefits of owning Bayer AG security.